Cargando…
Effects of conventional therapeutic interventions on the number and function of regulatory T cells
Several lines of investigation have revealed the apparent interplay between the immune system of the host and many conventional, “standard-of-care” anticancer therapies, including chemotherapy and small molecule targeted therapeutics. In particular, preclinical and clinical studies have demonstrated...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862634/ https://www.ncbi.nlm.nih.gov/pubmed/24353914 http://dx.doi.org/10.4161/onci.27025 |
_version_ | 1782295765948825600 |
---|---|
author | Roselli, Mario Cereda, Vittore di Bari, Maria Giovanna Formica, Vincenzo Spila, Antonella Jochems, Caroline Farsaci, Benedetto Donahue, Renee Gulley, James L Schlom, Jeffrey Guadagni, Fiorella |
author_facet | Roselli, Mario Cereda, Vittore di Bari, Maria Giovanna Formica, Vincenzo Spila, Antonella Jochems, Caroline Farsaci, Benedetto Donahue, Renee Gulley, James L Schlom, Jeffrey Guadagni, Fiorella |
author_sort | Roselli, Mario |
collection | PubMed |
description | Several lines of investigation have revealed the apparent interplay between the immune system of the host and many conventional, “standard-of-care” anticancer therapies, including chemotherapy and small molecule targeted therapeutics. In particular, preclinical and clinical studies have demonstrated the important role of regulatory T cells (Tregs) in inhibiting immune responses elicited by immunotherapeutic regimens such as those based on anticancer vaccines or checkpoint inhibitors. However, how the number and immunosuppressive function of Tregs change in cancer patients undergoing treatment with non-immune anticancer therapies remains to be precisely elucidated. To determine whether immunostimulatory therapies can be employed successfully in combination with conventional anticancer regimens, we have investigated both the number and function of Tregs obtained from the peripheral blood of carcinoma patients before the initiation and during the course of chemotherapeutic and targeted agent regimens. Our studies show that the treatment of breast cancer patients with tamoxifen plus leuprolide, a gonadotropin releasing hormone agonist, has minimal effects on Tregs, while sunitinib appears to exert differential effects on Tregs among patients with metastatic renal carcinoma. However, the administration of docetaxel to patients with metastatic prostate or breast cancer, as well as that of cisplatin plus vinorelbine to non-small cell lung cancer patients, appears to significantly increase the ratio between effector T cells and Tregs and to reduce the immunosuppressive activity of the latter in the majority of patients. These studies provide the rationale for the selective use of active immunotherapy regimens in combination with specific standard-of-care therapies to achieve the most beneficial clinical outcome among carcinoma patients. |
format | Online Article Text |
id | pubmed-3862634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Landes Bioscience |
record_format | MEDLINE/PubMed |
spelling | pubmed-38626342013-12-18 Effects of conventional therapeutic interventions on the number and function of regulatory T cells Roselli, Mario Cereda, Vittore di Bari, Maria Giovanna Formica, Vincenzo Spila, Antonella Jochems, Caroline Farsaci, Benedetto Donahue, Renee Gulley, James L Schlom, Jeffrey Guadagni, Fiorella Oncoimmunology Original Research Several lines of investigation have revealed the apparent interplay between the immune system of the host and many conventional, “standard-of-care” anticancer therapies, including chemotherapy and small molecule targeted therapeutics. In particular, preclinical and clinical studies have demonstrated the important role of regulatory T cells (Tregs) in inhibiting immune responses elicited by immunotherapeutic regimens such as those based on anticancer vaccines or checkpoint inhibitors. However, how the number and immunosuppressive function of Tregs change in cancer patients undergoing treatment with non-immune anticancer therapies remains to be precisely elucidated. To determine whether immunostimulatory therapies can be employed successfully in combination with conventional anticancer regimens, we have investigated both the number and function of Tregs obtained from the peripheral blood of carcinoma patients before the initiation and during the course of chemotherapeutic and targeted agent regimens. Our studies show that the treatment of breast cancer patients with tamoxifen plus leuprolide, a gonadotropin releasing hormone agonist, has minimal effects on Tregs, while sunitinib appears to exert differential effects on Tregs among patients with metastatic renal carcinoma. However, the administration of docetaxel to patients with metastatic prostate or breast cancer, as well as that of cisplatin plus vinorelbine to non-small cell lung cancer patients, appears to significantly increase the ratio between effector T cells and Tregs and to reduce the immunosuppressive activity of the latter in the majority of patients. These studies provide the rationale for the selective use of active immunotherapy regimens in combination with specific standard-of-care therapies to achieve the most beneficial clinical outcome among carcinoma patients. Landes Bioscience 2013-10-01 2013-11-01 /pmc/articles/PMC3862634/ /pubmed/24353914 http://dx.doi.org/10.4161/onci.27025 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Original Research Roselli, Mario Cereda, Vittore di Bari, Maria Giovanna Formica, Vincenzo Spila, Antonella Jochems, Caroline Farsaci, Benedetto Donahue, Renee Gulley, James L Schlom, Jeffrey Guadagni, Fiorella Effects of conventional therapeutic interventions on the number and function of regulatory T cells |
title | Effects of conventional therapeutic interventions on the number and function of regulatory T cells |
title_full | Effects of conventional therapeutic interventions on the number and function of regulatory T cells |
title_fullStr | Effects of conventional therapeutic interventions on the number and function of regulatory T cells |
title_full_unstemmed | Effects of conventional therapeutic interventions on the number and function of regulatory T cells |
title_short | Effects of conventional therapeutic interventions on the number and function of regulatory T cells |
title_sort | effects of conventional therapeutic interventions on the number and function of regulatory t cells |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862634/ https://www.ncbi.nlm.nih.gov/pubmed/24353914 http://dx.doi.org/10.4161/onci.27025 |
work_keys_str_mv | AT rosellimario effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells AT ceredavittore effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells AT dibarimariagiovanna effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells AT formicavincenzo effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells AT spilaantonella effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells AT jochemscaroline effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells AT farsacibenedetto effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells AT donahuerenee effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells AT gulleyjamesl effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells AT schlomjeffrey effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells AT guadagnifiorella effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells |